Biomarker and health marker study in myotonic dystrophy type 1
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study measures physical and lab “health markers” in people with myotonic dystrophy type 1 (DM1) to better understand how the disease changes over time. Some participants may also have a muscle biopsy to study tissue differences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 70 years old
- You have a confirmed DM1 diagnosis (by genetic test or clinical research criteria)
- You can give informed consent (and you’re able to follow study instructions)
- You do not have major uncontrolled kidney/liver problems, uncontrolled diabetes, or uncontrolled thyroid problems
- You are not currently using alcohol or other substances in an uncontrolled way
- You are not already enrolled in another DM1 trial (and haven’t been in one in the last 6 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ATX-01 for people with myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness. The study aims to see if ATX-01 can help reduce symptoms like muscle stiffness (myotonia) and improve daily function.
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This study follows people with myotonic dystrophy type 1 (DM1) over time to learn more about how the disease progresses. It collects health information and samples to help improve care.
This study follows people with myotonic dystrophy (DM1 or DM2) for 2 years to learn more about the disease. You must already be in the DM-Scope registry and have certain medical records available.
This study tests whether remote assessments can track myotonic dystrophy type 1 (DM1) and looks at genetic factors. It aims to find better ways to monitor the disease from home.
This study builds a registry of people and families affected by myotonic dystrophy types 1 and 2. It helps researchers learn about the condition over time and may support future studies that could lead to better care.
Hear when a new Myotonic Dystrophy 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.